Late relapses (>5 years, retrospectively included AMLs) n=5
Relapse vs diagnosis analysis n=22
Xenotransplantation assays n=19
Xenotransplantation assays (retrospectively included AMLs) n=19
Colony assays n=28 Supplementary Figure 2 | Summary of single cell derived colony assays in seven patients with normal karyotype. a, PCR amplification plots of allele-specific SNP (AS) assays in five colonies (colonies: columns; mutations: rows) from UPN2014-041 as in Fig.1a . b, Allele specific PCR amplification plots, as in Fig.1a , and traces of high resolution sizing of fluorescent PCR amplicons of FLT3 in bulk AML and four colonies from patient UPN2014-020. c, d, e, f, g, h, i, Results of AS assays in 7 patients as in figure 1. For each patient, the cell phenotype before culture and the number of analysed colonies are indicated above the table. Yellow box means no data. 
Supplementary Figure 4 | Temporal evolution of AML clones at relapse. Clonal composition of 22
AMLs at diagnosis and at relapse. The numbers of stable or variegating lesions are plotted as droplets above or below the time axis, respectively. Except for two cases (patients UPN2014-016 and UPN2014-027) with no changes in clonal composition (circles), coloured droplets of single patients are connected by vertical dashed lines. Droplets and circles are filled with dots that represent individual lesions from the four categories listed in the key, and summarized for each patient in connected boxes as indicated. Stable and variegating lesions are listed in coloured boxes below or above the time axis as indicated. Figure 3a . b, Clonal composition of injected samples (left panel) and repopulating human cells after engraftment (right panel) in nine patients with overt leukaemic engraftment. VAFs are indicated for mutations. FLT3-ITD was detected by high resolution sizing of PCR products. Chromosomal aberrations were quantified using karyotype or interphasic FISH results and conversion of VAFs to cell fractions when informative SNPs were available. In post engraftment sample, Inv(16) was studied using RT-PCR for the CBFB-MYH11 transcript. *, For patient UPN2015-057, cells from relapse AML were injected, but only cells from diagnosis were available for clonal composition studies. 46, XX, der(7)t(7;10)(q2?1;p12), der(10)t(7;10;11)(q2?1;p12;q23)inv(11 )(q13q23), der (11) ABCB11  DNM2  MAML1  SH2B3  ACSS3  DNMT3A MAP2K1 SHKBP1  AKAP13  DOK2  MAP2K2  SMC1A  APH1A  DSCAM  MLL  SMC3  ARHGEF2  EED  MLL2  SPI1  ASXL1  EGR1  MPL  SRSF2  ASXL2  ERCC2  MSR1  SSRP1  ATM  ETV6  MYBL2  STAG1  BCLAF1  EZH2  NCOA7  STAG2  BCOR  FBXW7  NCSTN  STAT3  BCORL1  FLT3  NF1  SUZ12  BOC  FOXP1  NMNAT2  TEK  BRAF  FZD1  NOTCH1  TERC  BRPF1  GATA1  NOTCH2  TERT  CBL  GATA2  NPM1  TET2  CBLB  GATAD2B  NRAS  TET3  CCND3  GBP4  NSD1  TLE4  CDKN2A  GDF5  NUMA1  TP53  CDKN2B  GLI1  PBRM1  TP73  CEBPA  HJURP  PDS5B  TYK2  CHEK2  HRAS  PHF6  U2AF1  CSF3R  IDH1  PTEN  WAC  CTCF  IDH2  PTPN11  WT1  CUL3  IKZF1  RAD21  XRCC1  CUX1  ITGAX  RB1  XRCC3  CUX2  JAK1  RBMX  ZRSR2  CXXC4  JAK2  RET  DAAM2  JAK3  RUNX1  DAXX  JARID2  SETBP1  DDX1  KDM6A  SF3A1  DDX41  KIT  SF3B1  DIS3 KRAS SH2B2 
Supplementary
Supplementary Table 8 | deep sequencing analyses in twelve patients at diagnosis relapse or in complete remission at different steps of follow-up. Data show the numbers of amplicon families (see methods) with the known alterated bases, alternative (non alterated/non reference) bases, and the total number of amplicon families (amplicons). 
